Physician profile
Danielle D Decourcey
NPI 1073001632
$625.35
in general payments reported to CMS, 2019-2025
11 companies · $59.42 in 2025
The $59.42 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.63 · 2024: $473 · 2025: $59.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $165.88 | 2024 | Azstarys |
| Tarsus Pharmaceuticals, INC. | $147.73 | 2024 | Xdemvy |
| Ironshore Pharmaceuticals INC. | $76.35 | 2024 | |
| Merck Sharp & Dohme LLC | $55.70 | 2022-2024 | M-M-R II, Gardasil, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $39.20 | 2025 | |
| Sanofi Pasteur INC. | $34.63 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $24.49 | 2024 | Ycanth |
| Seqirus USA INC | $23.66 | 2022 | |
| Pfizer INC. | $21.58 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.22 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Decourcey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.